Table 3: Invasive and noninvasive tests for advanced liver disease in First Nations and Non-First Nations patients with nonalcoholic fatty liver disease.

   First NationsNon-First Nations
Variable
%%

Liver histology
 Liver biopsy performed1133.38518.90.045
 NASH 436.42428.20.84
 Grade 0–2 inflammation 111007790.60.63
 Grade 3-4 inflammation 0033.5
 Stage 0–2 fibrosis111007790.60.63
 Stage  3-4 fibrosis0089.4
APRI
 APRI at baseline0.67 ± 0.8 0.75 ± 1.2 0.63
 APRI at follow-up0.51 ± 0.3 0.50 ± 0.4 0.97
NAFLD fibrosis score0.74
 Predictive of F0–F2 fibrosis2060.629966.6
 Indeterminate score1030.311224.9
 Predictive of F3-F4 fibrosis39.1388.5

Results represent mean ± SD.
From Angulo et al. [42]: the NAFLD fibrosis score, a noninvasive system that identifies liver fibrosis in patients with NAFLD.
NASH: nonalcoholic steatohepatitis; APRI: AST-to-Platelet Ratio Index; NAFLD: nonalcoholic fatty liver disease.